Compare CDE & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDE | VTRS |
|---|---|---|
| Founded | 1928 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Precious Metals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 18.3B |
| IPO Year | 1994 | 2019 |
| Metric | CDE | VTRS |
|---|---|---|
| Price | $17.49 | $15.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $22.40 | $13.50 |
| AVG Volume (30 Days) | ★ 24.3M | 8.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | ★ 533.33 | N/A |
| EPS | ★ 0.35 | 0.15 |
| Revenue | $709,598,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $165.39 | $4.41 |
| Revenue Next Year | $12.10 | $1.96 |
| P/E Ratio | ★ $50.39 | $101.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.49 | $8.63 |
| 52 Week High | $27.77 | $17.53 |
| Indicator | CDE | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 47.84 | 41.18 |
| Support Level | $16.16 | $12.90 |
| Resistance Level | $17.88 | $16.51 |
| Average True Range (ATR) | 1.08 | 0.45 |
| MACD | 0.09 | -0.09 |
| Stochastic Oscillator | 48.60 | 25.45 |
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada, and Mexico generating maximum revenue from United States.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.